The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.
The in-vitro activities of moxifloxacin, ciprofloxacin, erythromycin and rifampicin against 49 Legionella spp. isolates were determined by an agar dilution method with buffered charcoal yeast extract agar containing alpha-ketoglutarate. Because the inhibitory effects of charcoal in the test media were pronounced (92% for quinolones, 90.5% for rifampicin and 92.5% for erythromycin), the MICs were corrected for the charcoal-bound fraction of the antibiotics. The corrected geometric mean MICs were 0.018 mg/L for moxifloxacin, 0.02 mg/L for ciprofloxacin, 0.27 mg/L for erythromycin and 0.005 mg/L for rifampicin.
Ruckdeschel
G
G
Bayer AG, Pharma Research Centre, Wuppertal, Germany.
Dalhoff
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D001372:Aza Compounds; D002939:Ciprofloxacin / Q000494:pharmacology; D003470:Culture Media; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D007875:Legionella / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines; D012293:Rifampin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D001372:Aza Compounds; D003470:Culture Media; D024841:Fluoroquinolones; D011804:Quinolines; D002939:Ciprofloxacin; D004917:Erythromycin; D000077266:Moxifloxacin; D012293:Rifampin